Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 18/20 | 0.46 |
| ▸ | BDKRB2 | P30411 | 7/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3405377 | 0.89 | RAB9A (0.45) | BDKRB1BDKRB2RAB9AMEN1KMT2A | |
| SCHEMBL3311108 | 0.81 | BDKRB1 (0.47) | BDKRB1BDKRB2RAB9AMEN1KMT2A | |
| SCHEMBL3410238 | 0.81 | BDKRB1 (0.47) | BDKRB1BDKRB2RAB9AMEN1KMT2A | |
| SCHEMBL3404305 | 0.81 | RAB9A (0.50) | BDKRB1BDKRB2RAB9AMEN1KMT2A | |
| SCHEMBL3411012 | 0.77 | BDKRB1 (0.44) | BDKRB1BDKRB2RAB9AMEN1KMT2A | |
| SCHEMBL3313124 | 0.76 | BDKRB1 (0.44) | BDKRB1BDKRB2RAB9AMEN1KMT2A | |
| SCHEMBL4305019 | 0.76 | BDKRB1 (0.49) | BDKRB1BDKRB2RAB9AMEN1KMT2A | |
| SCHEMBL3410941 | 0.73 | BDKRB1 (0.49) | BDKRB1BDKRB2 | |
| SCHEMBL700245 | 0.73 | BDKRB1 (0.49) | BDKRB1BDKRB2MEN1KMT2A | |
| SCHEMBL4374587 | 0.73 | BDKRB1 (0.47) | BDKRB1BDKRB2RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8278319-B2 | Substituted spiroamine compounds | GRUENENTHAL GMBH (DE) | 2012-10-02 | — | — | US | claimed |
| US-8278319-B2 | Substituted spiroamine compounds | GRUENENTHAL GMBH (DE) | 2012-10-02 | — | — | US | disclosed |
| US-20100113417-A1 | Substituted Spiroamine Compounds | GRUENENTHAL GMBH (DE) | 2010-05-06 | — | — | US | disclosed |
| US-20100113417-A1 | Substituted Spiroamine Compounds | GRUENENTHAL GMBH (DE) | 2010-05-06 | — | — | US | disclosed |
| US-20100113417-A1 | Substituted Spiroamine Compounds | GRUENENTHAL GMBH (DE) | 2010-05-06 | — | — | US | disclosed |
| WO-2010049146-A1 | SUBSTITUTED SPIROAMINES | Grünenthal GmbH (DE) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113417-A1 | Substituted Spiroamine Compounds | BDKRB1, BDKRB2, REN | BDKRB1 1/4885BDKRB2 2/4885RAB9A 924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.